Citadel Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-43,193
| Closed | -$164K | – | 10876 |
|
|
2020
Q1 | $164K | Buy |
+43,193
| New | +$186K | ﹤0.01% | 8208 |
|
|
2019
Q4 | – | Sell |
-17,198
| Closed | -$91K | – | 10102 |
|
|
2019
Q3 | $87K | Buy |
17,198
+1,042
| +6% | +$5.2K | ﹤0.01% | 8544 |
|
|
2019
Q2 | $100K | Sell |
16,156
-458,146
| -97% | -$2.21M | ﹤0.01% | 8533 |
|
|
2019
Q1 | $2.2M | Sell |
474,302
-1,104,258
| -70% | -$5M | ﹤0.01% | 4304 |
|
|
2018
Q4 | $6.63M | Sell |
1,578,560
-60,424
| -4% | -$308K | ﹤0.01% | 2405 |
|
|
2018
Q3 | $10.3M | Buy |
1,638,984
+1,502,039
| +1,097% | +$11.5M | ﹤0.01% | 2063 |
|
|
2018
Q2 | $1.1M | Buy |
136,945
+32,256
| +31% | +$246K | ﹤0.01% | 5047 |
|
|
2018
Q1 | $781K | Buy |
104,689
+34,242
| +49% | +$228K | ﹤0.01% | 5180 |
|
|
2017
Q4 | $419K | Buy |
70,447
+47,130
| +202% | +$286K | ﹤0.01% | 5919 |
|
|
2017
Q3 | $172K | Sell |
23,317
-27,808
| -54% | -$177K | ﹤0.01% | 6792 |
|
|
2017
Q2 | $347K | Sell |
51,125
-80,126
| -61% | -$591K | ﹤0.01% | 5675 |
|
|
2017
Q1 | $1.24M | Buy |
131,251
+111,547
| +566% | +$1.11M | ﹤0.01% | 3702 |
|
|
2016
Q4 | $170K | Sell |
19,704
-99,012
| -83% | -$732K | ﹤0.01% | 6420 |
|
|
2016
Q3 | $751K | Buy |
+118,716
| New | +$718K | ﹤0.01% | 4229 |
|
|
2016
Q2 | – | Sell |
-22,909
| Closed | -$111K | – | 7673 |
|
|
2016
Q1 | $100K | Buy |
+22,909
| New | +$102K | ﹤0.01% | 6029 |
|
|
2015
Q4 | – | Sell |
-88,594
| Closed | -$581K | – | 9423 |
|
|
2015
Q3 | $507K | Buy |
88,594
+17,269
| +24% | +$133K | ﹤0.01% | 4794 |
|
|
2015
Q2 | $532K | Buy |
71,325
+32,950
| +86% | +$199K | ﹤0.01% | 4864 |
|
|
2015
Q1 | $230K | Sell |
38,375
-119,254
| -76% | -$751K | ﹤0.01% | 6014 |
|
|
2014
Q4 | $1.19M | Buy |
157,629
+126,468
| +406% | +$757K | ﹤0.01% | 3545 |
|
|
2014
Q3 | $162K | Buy |
31,161
+24,031
| +337% | +$120K | ﹤0.01% | 5948 |
|
|
2014
Q2 | $31K | Sell |
7,130
-9,595
| -57% | -$36.6K | ﹤0.01% | 7066 |
|
|
2014
Q1 | $68K | Sell |
16,725
-79,392
| -83% | -$406K | ﹤0.01% | 6519 |
|
|
2013
Q4 | $512K | Sell |
96,117
-58,430
| -38% | -$257K | ﹤0.01% | 3989 |
|
|
2013
Q3 | $778K | Sell |
154,547
-242,707
| -61% | -$1.32M | ﹤0.01% | 3354 |
|
|
2013
Q2 | $1.77M | Buy |
+397,254
| New | +$1.78M | ﹤0.01% | 2617 |
|
Other funds holding PGNX
Citadel Advisors's PGNX Position: Q2 2020 in Review
Citadel Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 43,193 shares — an estimated $164K sold.
Citadel Advisors first reported a position in PGNX in Q2 2013 and held it in 25 quarters. The position peaked at $10.3M in Q3 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Citadel Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Citadel Advisors sold 43,193 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $164K.
- Citadel Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's Progenics Pharmaceuticals Inc position peaked at $10.3M in Q3 2018.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.